BridgeBio Pharma Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BBIO Nasdaq 2834 http://bridgebio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BridgeBio Pharma Inc

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Jul 6th, 2020 8:30 pm
Hedge Funds Are Nibbling On BridgeBio Pharma, Inc. (BBIO) - Jul 5th, 2020 7:43 pm
Benzinga's Top Upgrades, Downgrades For June 25, 2020 - Jun 25th, 2020 2:10 pm
BridgeBio Pharma, Inc. Appoints Biotech Trailblazers Brent Saunders and Randy Scott and Renowned Economist Andrew Lo to Board of Directors - Jun 24th, 2020 11:30 am
BridgeBio Pharma and University of Florida Establish Collaboration to Advance Therapies for Genetically Driven Diseases - Jun 18th, 2020 11:35 am
BridgeBio Pharma, Inc. Enters Into Collaboration Agreement With Johns Hopkins University to Accelerate Development of New Medicines in Genetically Driven Diseases - Jun 18th, 2020 11:30 am
BridgeBio Pharma’s ML Bio Solutions Announces Dosing of First Subject in Phase 1 Clinical Trial of BBP-418 For Limb Girdle Muscular Dystrophy Type 2i (LGMD2i) - Jun 11th, 2020 11:00 am
7 Growth Stocks to Buy for Oodles of Upside - Jun 5th, 2020 6:43 pm
21 Risky Stocks That Might Have Borrowed More Than Is Good For Them - May 19th, 2020 1:37 pm
BridgeBio Pharma’s Phoenix Tissue Repair Provides Updates to its Recessive Dystrophic Epidermolysis Bullosa (RDEB) Program and Announces New Leadership Appointments - May 13th, 2020 8:10 pm
BridgeBio Pharma, Inc. Reports First Quarter 2020 Financial Results and Business Update - May 13th, 2020 8:01 pm
BridgeBio Pharma, Inc. To Present At Upcoming Investor Conference - May 6th, 2020 8:30 pm
Is BridgeBio Pharma, Inc. (BBIO) A Good Stock To Buy? - Apr 7th, 2020 1:53 am
BridgeBio Pharma’s QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations - Mar 12th, 2020 11:30 am
BridgeBio Pharma, Inc. Prices Upsized Offering of $475 Million Convertible Senior Notes - Mar 5th, 2020 4:32 am
BridgeBio Pharma, Inc. Announces Proposed Offering of $350 Million Convertible Senior Notes - Mar 4th, 2020 12:00 pm